AstraZeneca PLC
NYSE:AZNDrug Manufacturers - General
-$3.04 today
- Market cap
- $277.23B
- Beta
- 0.21
- P/E (TTM)
- 25.7
- EPS (TTM)
- $6.75
- Dividend yield
- 1.80%
Volume 2.54M
Average 1.96M
AZN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
AstraZeneca PLCNYSE: AZN
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue growth accelerates
Q3 FY2026 cost of revenue of $4.06B rose 45.0% year over year, ahead of the +20.9% change in trailing-twelve-month cost of revenue. Sequentially, it rose 60.9% from the prior quarter. Over 3 fiscal years it compounded at -5.0% a year.
Context
- Cost of revenue amounted to 18.1% of revenue in FY2025, down 0.8 pp from a year earlier.
- Cost of revenue increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +45.0% holds above the trailing-twelve-month pace of +20.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 10.63B USD
- Year-over-year change
- +4.2%
- 4-year CAGR
- -3.8%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 10.63B | +4.2% |
| FY2024 | 2024-12-31 | 10.21B | +23.5% |
| FY2023 | 2023-12-31 | 8.27B | -33.3% |
| FY2022 | 2022-12-31 | 12.39B | -0.4% |
| FY2021 | 2021-12-31 | 12.44B | — |
Cost of Revenue vs competitors
How AZN compares with its peers on the latest reported figures
- Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +20.9% is the 3rd highest of 10, against a peer median of +4.5%.
- Cost of revenue amounts to 19.9% of revenue for AZN, versus a peer median of 25.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 63.75B DKK | +27.3% | +27.4% | 19.4% | |
| LTM Sep 2026 | $30.98B USD | +5.3% | +7.1% | 31.2% | |
| LTM Jun 2026 | $17.08B USD | -4.0% | -22.4% | 26.8% | |
| LTM Jun 2026 | $16.35B USD | +4.5% | +1.5% | 24.6% | |
| LTM Sep 2026 | $15.68B USD | -13.1% | +1.5% | 23.7% | |
| LTM Jun 2026 | $14.68B USD | +3.6% | +11.2% | 29.8% | |
| LTM Jun 2026 | $14.22B USD | +8.5% | +5.7% | 25.6% | |
| LTM Jun 2026 | $13.23B USD | +43.0% | +18.6% | 16.6% | |
| LTM Sep 2026 | $12.38B USD | +20.9% | -5.0% | 19.9% | |
| LTM Jun 2026 | $10.43B USD | -15.9% | +18.8% | 27.3% | |
| Peer median (excluding AZN) | — | +4.5% | +7.1% | 25.6% | |
Competitors are the stored peer set for AZN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 37.42B | 44.35B | 45.81B | 54.07B | 58.74B |
| Cost of Revenue | 12.44B | 12.39B | 8.27B | 10.21B | 10.63B |
| Gross Profit | 24.98B | 31.96B | 37.54B | 43.87B | 48.11B |
| Gross Margin | 66.8% | 72.1% | 82.0% | 81.1% | 81.9% |
| Research & Development | 9.74B | 9.76B | 10.94B | 13.58B | 14.23B |
| Selling, General & Admin | 15.59B | 17.98B | 18.22B | 20.22B | 20.51B |
| Operating Expenses | 23.92B | 28.2B | 29.35B | 33.86B | 34.36B |
| Depreciation & Amortization | 4.1B | 5.25B | 4.93B | 5.07B | 5.73B |
| EBITDA | 5.11B | 9.09B | 13.42B | 15.44B | 19.83B |
| EBITDA Margin | 13.7% | 20.5% | 29.3% | 28.6% | 33.8% |
| Operating Income | 1.06B | 3.76B | 8.19B | 10B | 13.74B |
| Operating Margin | 2.8% | 8.5% | 17.9% | 18.5% | 23.4% |
| Interest Income | 43M | 81M | 301M | 345M | 360M |
| Interest Expense | 1.28B | 1.33B | 1.59B | 1.68B | 1.69B |
| Other Income / Expenses | (1.32B) | (1.26B) | (1.29B) | (1.31B) | (1.34B) |
| Income Before Tax | (265M) | 2.5B | 6.9B | 8.69B | 12.4B |
| Pre-Tax Margin | -0.7% | 5.6% | 15.1% | 16.1% | 21.1% |
| Income Tax Expense | (380M) | (792M) | 938M | 1.65B | 2.17B |
| Net Income | 112M | 3.29B | 5.96B | 7.04B | 10.26B |
| Net Margin | 0.3% | 7.4% | 13.0% | 13.0% | 17.5% |
| EPS (Basic) | 0.08 | 2.12 | 3.81 | 4.54 | 6.60 |
| EPS (Diluted) | 0.08 | 2.11 | 3.81 | 4.50 | 6.54 |
| Weighted Avg Shares | 1.42B | 1.55B | 1.56B | 1.55B | 1.55B |
| Weighted Avg Shares (Diluted) | 1.43B | 1.56B | 1.56B | 1.56B | 1.56B |
AstraZeneca PLC
NYSE:AZN
Intrinsic Alpha fair value
Locked
Current Price
$178.76
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.